Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Phase I/II Trial Of Tremelimumab In Patients With Metastatic Melanoma.

L. Camacho, S. Antonia, J. Sosman, J. Kirkwood, T. Gajewski, B. Redman, D. Pavlov, C. Bulanhagui, V. Bozon, J. Gomez-Navarro, A. Ribas
Published 2009 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
PURPOSE Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade with tremelimumab (CP-675,206), a fully human anti-CTLA4 monoclonal antibody, was tolerated and demonstrated antitumor activity in a single dose, dose-escalation phase I trial in patients with solid tumors. This phase I/II trial was conducted to examine safety of multiple doses of tremelimumab, to further assess efficacy, and to identify an appropriate dosing regimen for further development. PATIENTS AND METHODS Twenty-eight patients with metastatic melanoma received monthly intravenous infusions of tremelimumab at 3, 6, or 10 mg/kg for up to 1 year to determine recommended monthly phase II dose. During phase II, 89 patients received tremelimumab 10 mg/kg once every month or 15 mg/kg every 3 months. RESULTS No dose-limiting toxicity was observed in phase I once every month dosing. In phase II, 8 (10%) of 84 response-assessable patients attained objective antitumor responses; best overall objective response was one complete response and three partial responses in each dosing regimen. Most responses were durable (range, 3 to 30+ months). Most frequent treatment-related adverse events (AEs) were diarrhea, rash, and pruritus. Frequency of grade 3/4 AEs was 13% in the 15 mg/kg every 3 months arm and 27% in the 10 mg/kg once every month. Serious AEs were also less frequent in the 15 mg/kg once every 3 months cohort (9% v 23% in 10 mg/kg arm). CONCLUSION Multiple infusions of tremelimumab were generally tolerable and demonstrated single-agent antitumor activity. Both phase II regimens generated durable tumor responses. Based on its more favorable safety profile, 15 mg/kg every 3 months was selected for further clinical testing.
This paper references
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
E. Small (2007)
A phase II, randomized multi-center study of MDX-010 alone or in combination with dacarbazine (DTIC) in stage IV metastatic malignant melanoma.
E. Hersh (2004)
Evaluation of routine radiation boost following breast conservation therapy in young patient
J. Lamont (2004)
Chemotherapy for metastatic melanoma
H. Gogas (2007)
Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
Legha Ss (1997)
CD28/B7 system of T cell costimulation.
D. Lenschow (1996)
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody
L. Camacho (2008)
Targeting Nodal in malignant melanoma cells
L. Postovit (2007)
Expression and function of CTLA-4 in Th1 and Th2 cells.
M. Alegre (1998)
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.
A. Sasse (2007)
Next generation of immunotherapy for melanoma.
J. Kirkwood (2008)
Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
J. Weber (2007)
Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma
A. Ribas (2008)
Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): Analysis of long-term survival.
MichaelJ. Millward (2004)
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]
V. Chiarion-Sileni (2005)
A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects.
S. Strome (2007)
Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells.
M. S. Kuhns (2000)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
G. Phan (2003)
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
P. Chapman (1999)
A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma
J. Kirkwood (2008)
Expression and Function of Xmsx-2B in Dorso-Ventral Axis Formation in Gastrula Embryos
I. Onitsuka (2000)
Integration of intra-operative electron irradiation (IOERT) in breast conserving treatment for T1/T2N0 breast cancer: Early results of a phase II tria.
W. Wong (2004)
Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study
J. Gomez-Navarro (2007)
Safety of tremelimumab (CP-675,206) in patients (pts) with advanced cancer
N. Wallis (2008)
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
B. Comin-Anduix (2008)
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
A. Ribas (2005)
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
E. Korn (2008)

This paper is referenced by
Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma
D. Bajor (2018)
Immuno-Therapy with Anti-CTLA4 Antibodies in Tolerized and Non-Tolerized Mouse Tumor Models
J. Persson (2011)
Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
F. Petrelli (2016)
Co‐Administration of Co‐Stimulatory Moieties
Y. Latchman (2012)
Reply to K.S. Wilson et al.
A. Ribas (2013)
The antibody repertoire of colorectal cancer
S. W. Cha (2017)
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
G. Ku (2010)
Interface of Signal Transduction Inhibition and Immunotherapy in Melanoma
A. Shada (2010)
Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
B. Comin-Anduix (2010)
Immune Regulatory Antibodies: Are They the Next Advance?
J. Wolchok (2010)
Ipilimumab Induced Enterocolitis: A Fatal Immune-Related Adverse Event of Melanoma Treatment
Chandamuri Babi (2013)
CTLA‐4 to overcome immunological tolerance to melanoma
F. S. Hodi (2011)
Body composition and sarcopenia: The next‐generation of personalized oncology and pharmacology?
M. Hilmi (2019)
High-dose interleukin-2 in patients with metastatic melanoma whose disease progressed after biochemotherapy
A. Buzaid (2011)
Overcoming Cancer Tolerance with Immune Checkpoint Blockade
G. Clifton (2015)
Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy – Detecting Illusive Disease, Defining Response
Raymond Y Huang (2015)
Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies
U. Hegde (2017)
The Consequence of Immune Suppressive Cells in the Use of Therapeutic Cancer Vaccines and Their Importance in Immune Monitoring
M. Vergati (2011)
Improving the clinical efficacy of cancer vaccines by targeting immune suppression in human tumors
N. Demotte (2012)
The Immune Response to Tumors as a Tool toward Immunotherapy
F. Pandolfi (2011)
PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab.
A. Jazirehi (2016)
The role of checkpoints in the treatment of GBM
J. E. Kim (2015)
Cytotoxic T-lymphocyte antigen-4 blockade in melanoma.
Elizabeth I Buchbinder (2015)
Interaction between Targeted Therapy and Immunotherapy
P. A. Prieto (2018)
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Yinghao Zhao (2018)
CTLA-4 Antibodies in Cancer Immunotherapy
Veerendra Koppolu (2016)
Discovery of Novel Tubulin Inhibitors and Selective Survivin Inhibitors for Advanced Melanoma and Total Synthesis of Bioactive 20S-hydroxyvitamin D3
Qinghui Wang (2017)
Immunotherapy of Melanoma.
A. Snyder (2015)
Immunologic functions as prognostic indicators in melanoma
Marna G. Bouwhuis (2011)
Anti-CTLA-4 antibody adjuvant therapy in melanoma.
A. Eggermont (2010)
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
C. Boutros (2016)
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer.
M. Aglietta (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar